**Appendix Table C26. Outcome assessment: Comparator, rhabdomyosarcoma**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study (Investigator, country, year)** | **Record Number** | **Group (N)** | **Primary Outcomes** | **Secon-dary Out-comes** | **F/U Frequency/Duration** | **Comment** |
| Breneman, USA, 2003 | 75360 | Comparator (127) | Survival |   |   |   |
| Carli, Italy, 1999 | 16010 | Comparator | Overall Survival | Event Free survival |   |   |
| Grundy, UK, 2001 | 14200 |   |   |   |   |   |
| McDowell, UK, 2010 | 75350 | Comparator (45) | Survival | Harms | 30.16 months (0.69-105.40) |   |
| Pappo, USA, 1999 | 48020 | Comparator (605) | survival |   | five year survival botroid 64% (40-88), embryonal 26% (21-31), alveolar/undiff 5% (2-8) | histologic subtype at initial diagnosis associated with survival after recurrence, but survival not affected by site of recurrence. |
| Pappo, USA, 2001 | 47860 |   | Survival | Harms |   | number of metastatic sites influenced survival 1 or 2 vs. +2 |
| Sandler, USA, 2001 | 12810 | Comparator (152) | Survival | Harms |   | Patients who are < 10 or with embryonal RMS, or a GU primary site, or no nodal disease at presentation and patients lacking bone or bone marrow involvement at presentation fared significantly better. |
| Van Winkle, USA, 2005 | 43550 | Comparator(27) | Survival | Harms |   | Male gender (p=.015), Embryonal histology at recurrence (p=.005), and CR (p=.014) were associated in univariate analysis with improved survival |
| Williams, Canada, 2004 | 9010 | Comparator (13) | Survival | Event Free Survival |   |   |